权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Tumor-specific autoantibodies for SCLC early detection

用于 SCLC 早期检测的肿瘤特异性自身抗体

基本信息

批准号：
10299616
负责人：
A McGarry Houghton
金额：
$ 14.89万
依托单位：
FRED HUTCHINSON CANCER RESEARCH CENTER
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-12-17 至 2022-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10299616
关键词：
Accounting American Antibodies Antigens Autoantibodies Autoantigens Biological Assay Breast Cancer Center Cancer Etiology Cancer Patient Cessation of life Clinic Clinical Colon Carcinoma Complex Data Set Detection Development Diagnosis Diagnostic Disease Early Diagnosis Extensive Stage Generations Goals Human Hybrids Image Length Lesion Limited Stage Lung Malignant Neoplasms Malignant neoplasm of lung Methodology Minority Modality Modeling Molecular Neuraxis Nodule Non-Small-Cell Lung Carcinoma Outcome Ovarian Pancreas Paraneoplastic Syndromes Patients Plasma Prevention Process Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Proteins Proteomics Reproducibility Sampling Screening for cancer Specimen Survival Rate Testing Time Translating Validation Variant Women&apos s Health X-Ray Computed Tomography base biomarker panel candidate marker cardiovascular health case control chemotherapy clinical diagnosis clinical practice cohort computed tomography screening detection method detection platform early detection biomarkers high dimensionality implementation strategy improved lung cancer screening lung small cell carcinoma novel screening statistics tumor

项目摘要

ABSTRACT/SUMMARY Small cell lung cancer (SCLC) is one of the few malignancies with such poor outcomes that it meets the definition of a “recalcitrant” cancer, accounting for 30,000 American lives each year with five-year survival rates of just ~7%. Somewhat lost in these dismal statistics is the fact that patients diagnosed early (limited stage) display vastly superior survival metrics when compared to those diagnosed late (extensive stage). Unfortunately, only a minority of cases are identified at limited stage, and the computed tomography (CT) screening approaches capable of early detection for non-small cell lung cancer (NSCLC) have not proven effective for SCLC. We will employ a novel two-mode, array based, hybrid plasma marker methodology capable of detecting autoantibody- autoantigen complex and unbound autoantibody markers for SCLC early detection. One of the major problems with studying SCLC is there are few studies and cohorts that have appropriate plasma samples. We have accumulated robust biomarker candidates centered around autoantibody-antigen complexes using the Cardiovascular Health Study (prediagnostic), Fred Hutch Lung Cancer Early Detection and Prevention Clinic, and Vanderbilt SCLC sample sets and will comprehensively define free autoantibodies levels in these same cohorts. We propose to test a fixed combination rule combining both autoantibody approaches using all of the prediagnostic SCLC samples from the Women's Health Initiative (WHI), the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial (PLCO), and the National Lung Screening Trial (NLST) cohorts and diagnostic samples from Moffitt Cancer Center. Using prediagnostic samples allows us to effectively model early detection much more accurately than after diagnosis occurs, and this is particularly important for SCLC as diagnosis at the extensive stage is nearly almost always fatal. Part of our analysis will determine how early our autoantibody marker panel can predict the presence of SCLC and whether a tumor can be observed via CT at that time in order to evaluate the timing and implementation of our early-detection procedure.

抽象/总结